Market Cap | 403.07M | P/E | 12.44 | EPS this Y | 24.20% | Ern Qtrly Grth | - |
Income | 68.07M | Forward P/E | 4.83 | EPS next Y | -6.80% | 50D Avg Chg | 5.00% |
Sales | 139.92M | PEG | 6.97 | EPS past 5Y | - | 200D Avg Chg | -17.00% |
Dividend | N/A | Price/Book | 2.47 | EPS next 5Y | 1.00% | 52W High Chg | -79.00% |
Recommedations | - | Quick Ratio | 3.17 | Shares Outstanding | 71.09M | 52W Low Chg | 18.00% |
Insider Own | 9.40% | ROA | 23.26% | Shares Float | 40.25M | Beta | 0.97 |
Inst Own | 49.49% | ROE | 37.09% | Shares Shorted/Prior | 5.14M/5.11M | Price | 5.60 |
Gross Margin | 75.52% | Profit Margin | 48.65% | Avg. Volume | 984,787 | Target Price | - |
Oper. Margin | 78.71% | Earnings Date | Feb 29 | Volume | 790,960 | Change | -0.53% |
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Wedbush | Outperform | Nov 6, 12 |